Abstract
A total of 77 literatures till November 2020 were screened regarding various interventions to treat COVID-19patients, among which 16 and 15 studies fulfilling predefined exclusion and inclusion criteria were subjected toPairwise and Network meta-analysis respectively. In Pairwise meta-analysis, the recovery rate of treatment withLopinavir/Ritonavir versus other antiviral (OR= 0. 0381, CI= 0.0021-0.6870), placebo (OR= 0.6592, CI= 0.4207-1.0329), Remdesivir (OR= 0.5286, CI= 0.3915-0.7137) and standard care (OR= 0.9787, CI= 0.8523-1.1238) in fixedand random effect model with 95% confidence limit found statistically significant protection than those of allother treatment. In Network meta-analysis, recovery estimates sizes of treatment, in reference with other antivirals1.0000 (0.9917, 1.0000) shows less risk with treatment Standard care 0.7811 (0.6696, 0.8417), Remdesivir 0.7717(0.6491, 0.8144), Lopinavir/ Ritonavir 0.7801 (0.6701, 0.8473), Placebo 0.7219 (0.6178, 0.7836).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Indian Journal of Public Health Research & Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
